Lilly To Base Price Of COVID-19 Antibodies On Their Savings To System

By John Wilkerson / October 7, 2020 at 7:48 PM
Eli Lilly plans to price its coronavirus antibody candidates based on how much money they save by avoiding hospitalizations, emergency room visits “or other problems associated with COVID-19," and the company will tier pricing among countries so rich countries pay more than poor countries, Eli Lilly Chairman and CEO Dave Ricks said Wednesday (Oct. 7). President Donald Trump said later in the day that antibody drugs that Lilly and Regeneron are testing will be free to everyone and that both...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.